Financials Northwest Biotherapeutics, Inc. Börse Stuttgart
Stocks
NBYB
US66737P6007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1500 EUR | -6.25% |
|
-6.25% | -27.18% |
Projected Income Statement: Northwest Biotherapeutics, Inc.
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | 38.93 |
| Change | - | - | - | - |
| EBITDA | - | - | - | - |
| Change | - | - | - | - |
| EBIT 1 | - | - | -67.3 | -47.4 |
| Change | - | - | - | 29.58% |
| Interest Paid 1 | - | - | -9.13 | -9.526 |
| Earnings before Tax (EBT) | - | - | - | - |
| Change | - | - | - | - |
| Net income | -85.19 | -61.48 | - | - |
| Change | - | 27.84% | - | - |
| Announcement Date | 3/31/25 | 4/15/26 | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Northwest Biotherapeutics, Inc.
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Net Debt 1 | - | - | 96.1 | 125 |
| Change | - | - | - | 30.07% |
| Announcement Date | 3/31/25 | 4/15/26 | - | - |
1USD in Million
Estimates
Cash Flow Forecast: Northwest Biotherapeutics, Inc.
| Fiscal Period: December | 2026 | 2027 |
|---|---|---|
| CAPEX 1 | 1 | 1 |
| Change | - | 0% |
| Free Cash Flow (FCF) 1 | -51 | -40.76 |
| Change | - | 20.09% |
| Announcement Date | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: Northwest Biotherapeutics, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - | - | -121.73% |
| EBT Margin (%) | - | - | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | - | - | - |
| FCF margin (%) | - | - | - | - | - | - | - | -104.68% |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | -160.2% | -90.17% | -117.48% | -117.23% | -152.28% | -69.33% | - | - |
| ROE | 259.71% | -73.57% | 91.72% | 82.31% | 132.94% | 95.08% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | -1.88x | -3.07x |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | 2.57% |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | -1.96% | -2.45% |
Items per share | ||||||||
| Cash flow per share 1 | 0.012 | 0.016 | 0.006519 | 0.001808 | 0.001637 | 0.001939 | - | - |
| Change | - | 32.91% | -59.24% | -72.27% | -9.46% | 18.45% | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | -0.4375 | -0.1307 | -0.1199 | -0.056 | -0.0711 | -0.0385 | - | - |
| Change | - | 70.12% | 8.28% | 53.33% | -27.1% | 45.92% | - | - |
| EPS 1 | -0.7307 | -0.0598 | -0.1034 | -0.06 | -0.07 | -0.0422 | - | - |
| Change | - | 91.82% | -73.04% | 41.97% | -16.67% | 39.71% | - | - |
| Nbr of stocks (in thousands) | 822,716 | 947,622 | 1,058,132 | 1,172,382 | 1,324,666 | 1,566,728 | - | - |
| Announcement Date | 3/31/21 | 3/1/22 | 2/28/23 | 3/5/24 | 3/31/25 | 4/15/26 | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | - | - |
| EV / Sales | - | 10.5x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1719USD
Average target price
1.000USD
Spread / Average Target
+481.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- NWBO Stock
- NBYB Stock
- Financials Northwest Biotherapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
